BTIG analyst Kaveri Pohlman raised the firm’s price target on MacroGenics to $12 from $6 and keeps a Buy rating on the shares. The firm said that small modifications to both MGD024 and lorigerlimab increases its interest in the pipeline. BTIG added that it raised its price target on better visibility into MGC018’s commercial opportunity.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MGNX:
- MacroGenics price target raised to $8 from $7 at Citi
- MacroGenics price target raised to $14 from $12 at H.C. Wainwright
- MacroGenics downgraded to Neutral at Guggenheim on prostate cancer caution
- MacroGenics downgraded to Neutral from Buy at Guggenheim
- MacroGenics Provides Corporate Update and 2022 Financial Results
